Robert Gunning
Vermögen: - $ am 31.08.2026
Vermögen: - $ am 31.08.2026
Robert W.
Gunning is currently Principal Accounting Officer, VP & Controller at NewAmsterdam Pharma Co. NV since 2026.
Formerly, Mr. Gunning was Controller at Altimmune, Inc. in 2026 and Vice President-Finance & Controller at Y-mAbs Therapeutics, Inc. from 2022 to 2026.
Mr. Gunning completed undergraduate education at Pace University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.09.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Comptroller/Controller/Auditor | 10.08.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| ALTIMMUNE, INC. | Comptroller/Controller/Auditor | 01.07.2026 |
| YMAS THER | Comptroller/Controller/Auditor | 01.04.2026 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Pace University
Pace University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Altimmune, Inc.
Altimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
NewAmsterdam Pharma Co. NV
NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen